- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Case C-574/11: Reference for a preliminary ruling from the Landgericht Düsseldorf (Germany), lodged on 16 November 2011 — Novartis AG v Actavis Deutschland GmbH & Co KG, Actavis Ltd.
ECLI:EU:UNKNOWN:62011CN0574
62011CN0574
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
Official Journal of the European Union
C 32/13
(Case C-574/11)
2012/C 32/24
Language of the case: German
Referring court
Parties to the main proceedings
Applicant: Novartis AG
Defendants: Actavis Deutschland GmbH & Co KG, Actavis Ltd.
Question referred
Are Articles 4 and 5 of Regulation (EC) No 469/2009 to be interpreted as meaning that the protection conferred by a supplementary protection certificate, which has been granted for a single active ingredient (in this case, Valsartan), extends to a form which contains a combination of active ingredients featuring that single active ingredient (in this case, Valsartan + Hydrochlorothiazide)?
Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products (Codified version), OJ 2009 L 152, p. 1.
Language of the case: German
* * *